These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 26546295)

  • 41. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
    Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
    Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
    [No Abstract]   [Full Text] [Related]  

  • 43. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
    Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
    Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
    Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
    Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
    Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
    Russo M; Siravegna G; Blaszkowsky LS; Corti G; Crisafulli G; Ahronian LG; Mussolin B; Kwak EL; Buscarino M; Lazzari L; Valtorta E; Truini M; Jessop NA; Robinson HE; Hong TS; Mino-Kenudson M; Di Nicolantonio F; Thabet A; Sartore-Bianchi A; Siena S; Iafrate AJ; Bardelli A; Corcoran RB
    Cancer Discov; 2016 Feb; 6(2):147-153. PubMed ID: 26644315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
    Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
    Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A rare case of recurrent ovarian cancer with
    Endo Y; Watanabe T; Saito M; Saito K; Suzuki R; Sano H; Natori Y; Sasaki E; Ueda M; Kamo N; Furukawa S; Soeda S; Kono K; Saji S; Fujimori K
    Mol Clin Oncol; 2022 Apr; 16(4):90. PubMed ID: 35251641
    [No Abstract]   [Full Text] [Related]  

  • 51. Design, synthesis and biological activity of bicyclic carboxamide derivatives as TRK inhibitors.
    Sun M; Cai S; Li P; Zhang F; Zhang H; Zhou J
    Bioorg Med Chem; 2020 Dec; 28(23):115811. PubMed ID: 33069129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Entrectinib: First Global Approval.
    Al-Salama ZT; Keam SJ
    Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N of 2 Responders with LMNA-NTRK1.
    Lih CJ; Chen AP
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563357
    [No Abstract]   [Full Text] [Related]  

  • 54. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
    Greco A; Miranda C; Pierotti MA
    Mol Cell Endocrinol; 2010 May; 321(1):44-9. PubMed ID: 19883730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
    Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
    Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
    Siravegna G; Lazzari L; Crisafulli G; Sartore-Bianchi A; Mussolin B; Cassingena A; Martino C; Lanman RB; Nagy RJ; Fairclough S; Rospo G; Corti G; Bartolini A; Arcella P; Montone M; Lodi F; Lorenzato A; Vanzati A; Valtorta E; Cappello G; Bertotti A; Lonardi S; Zagonel V; Leone F; Russo M; Balsamo A; Truini M; Di Nicolantonio F; Amatu A; Bonazzina E; Ghezzi S; Regge D; Vanzulli A; Trusolino L; Siena S; Marsoni S; Bardelli A
    Cancer Cell; 2018 Jul; 34(1):148-162.e7. PubMed ID: 29990497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation.
    Attwa MW; Kadi AA; Alrabiah H; Darwish HW
    J Pharm Biomed Anal; 2018 Oct; 160():19-30. PubMed ID: 30055343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.